A lthough different cell types contribute to the increase in fibrillar collagen I levels during hepatic fibrogenesis, they all undergo a common process of differentiation and acquisition of a classic myofibroblast-like phenotype. Portal fibroblasts play a significant role in the development of portal fibrosis; however, hepatic stellate cells (HSCs) play a major role in collagen I deposition when hepatocellular injury is concentrated within the liver lobule and sinusoids.
Efforts to understand the pathogenesis of liver fibrosis focus on events that lead to the activation of profibrogenic cells and to early accumulation of scar (ie, fibrillar collagen I) to identify therapeutic targets to prevent its onset, slow its progression, or help its resolution. 1 Stimuli initiating activation, proliferation, migration, and invasion of HSCs derive from injured hepatocytes, 2, 3 Kupffer cells, 4, 5 sinusoidal endothelial cells (SECs), 6 and inflammatory cells 7 in addition to rapid changes in extracellular matrix (ECM) composition. 1 Synthesis of collagen I is regulated by the ECM itself, and even though the basement membrane matrix preserves quiescence of HSCs, collagen I further enhances HSC activation in a paracrine manner. Increasingly, reactive oxygen species (ROS) are viewed as candidate drivers of HSC activation and collagen I up-regulation 3, 4, 8, 9 ; however, downstream mediators for the ROS effects on the activation of HSCs and the increase in collagen I levels require further study.
Synthesis and secretion of collagen I are a major focus of interest, during the onset of liver fibrosis; nevertheless, there is also considerable deposition of proteoglycans, glycoproteins, and glycosaminglycans into the space of Disse. 10 Fibromodulin (FMOD) is a small leucine-rich proteoglycan regulating ECM organization, which has been described as essential for tissue repair in multiple organs. 11 This family of proteoglycans is involved in cell metabolism via binding to growth factors as well as in matrix organization by interacting with various collagens. [12] [13] [14] [15] Fmod Ϫ/Ϫ mice develop abnormal collagen fibril architecture in connective tissues in addition to showing increased age-dependent osteoarthritis and degenerative changes in cartilage structure 14, 16, 17 ; thus, FMOD plays a significant role in defining tissue integrity. 14 Moreover, in vivo both collagen and FMOD are likely to have an important functional role in tissues where they are coexpressed due to potential physical interaction between both proteins. 18 Thus far, there is no information on whether FMOD is present in the liver, which cells express it, and where specifically it is induced upon the establishment of hepatic injury. 19 In addition, little is known about its potential role in the development of liver fibrosis, 19 whether induction of FMOD in liver cells could contribute to the profibrogenic potential of HSCs, and the molecular mechanism involved in these events.
Identifying if FMOD stimulates the profibrogenic response to hepatic damage could be central for understanding the pathogenesis of liver fibrosis. Thus, the aim of this study was to explore how FMOD regulates the HSC profibrogenic phenotype, a key event in liver fibrosis, as well as the consequences of in vivo ablation of the Fmod gene for the fibrogenic response to liver injury under a profibrogenic stimuli. To investigate this, we used a coculture model that resembles aspects of the interplay between liver cells in addition to inducing liver fibrosis in vivo using wild-type (WT) and Fmod Ϫ/Ϫ mice. The results suggest that hepatic FMOD, sensitive to oxidant stress, contributes to HSC activation and collagen I deposition, thus participating in the pathogenesis of liver fibrosis.
Materials and Methods

Cell Treatments
Rat HSCs (250,000 cells/well) were seeded on 6-well plates in Dulbecco's modified Eagle medium/F12 with 10% fetal bovine serum. Primary cells were cultured using Dulbecco's modified Eagle medium/F12 for 4 to 7 days, which was replaced by serum-deprived Dulbecco's modified Eagle medium/F12 before treatment with 50 nmol/L endotoxin-free human recombinant FMOD (rFMOD) for 24 hours (donated by Dr Ake Oldberg, Lund University, Lund, Sweden). Cells were infected with Ad-LUC or Ad-FMOD at a multiplicity of infection of 50 for 48 hours. The adenoviruses were a gift from Dr David T. Curiel (Washington University, St Louis, MO). H 2 O 2 (25 mol/L) and catalase (200 U/mL) were added to the cells for 24 hours (both from Sigma, St Louis, MO).
Mice
Fmod Ϫ/Ϫ mice and their WT littermates (C57BL/6J) were obtained from Dr Marian Young (National Institutes of Health, Bethesda, MD). 20, 21 These mice were backcrossed for at least 10 generations. Colonies were established by intercrossing Fmod ϩ/Ϫ mice, and littermates were used in all experiments. Fmod Ϫ/Ϫ mice have normal heart, liver, lung, skin, and cartilage; however, they show abnormal tissue organization, collagen fiber bundles, and fiber architecture. 22 
Induction of Liver Injury
Ten-week-old male WT mice and their Fmod Ϫ/Ϫ littermates were used in all experiments. To induce liver injury, 3 in vivo models were used. In the first model, cholestasis was induced by placing a ligature around the common bile duct while controls were sham operated. All mice were killed 3 weeks later.
In the second model, mice were intraperitoneally injected twice a week with 0.5 mL/kg body wt CCl 4 (Sigma) or an equal volume of mineral oil for 1 month and killed 48 hours after the last injection of CCl 4 . In the third model, mice were treated with thioacetamide (TAA) (300 mg/L; Sigma) in the drinking water or received an equal volume of water for 4 months. Mice were killed 48 hours after withdrawal of TAA. Blood was collected by orbital venous plexus bleeding. Each liver was excised into fragments by using the same liver lobe for biochemical assays and paraffin embedding for staining. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health.
Human Samples
Dr Andrea D. Branch (Mount Sinai School of Medicine, New York, NY) provided the human liver protein lysates and RNA from resections from de-identified controls and subjects with biopsy-proven stage 3 hepatitis C virus (HCV) cirrhosis. Samples were scored according to the Scheuer/Ludwig Batts classification. 23, 24 These samples were exempt from institutional review board approval because no patient information was disclosed.
Pathology
In all experiments, the left liver lobe was excised and fixed in 10% neutral-buffered formalin and processed into paraffin sections for H&E or immunohistochemistry (IHC) and scoring by the Brunt classification. Portal and lobular inflammation were noted to be lymphocytes present in the lobules or portal areas and were scored as follows: 1 ϭ rare foci; 2 ϭ up to 5 foci; 3 ϭ Ͼ5 foci. Centrilobular necrosis and parenchymal necrosis were each separately scored. The scores for centrilobular necrosis were as follows: 1 ϭ hepatocyte necrosis affecting only zone 3; 2 ϭ in addition to zone 3 necrosis, occasional bridging necrosis was seen; 3 ϭ pronounced bridging and confluent necrosis. Parenchymal necrosis was noted to be spotty necrosis or apoptosis in zones 2 and 1. The scores for parenchymal necrosis were as follows: 1 ϭ Յ1 focus; 2 ϭ 5-10 foci; 3 ϭ Ն10 foci at 100ϫ. Ductular reaction was noted to be proliferation of bile ductules at the margins of the portal tracts, and the score was as follows: 1 ϭ rare bile ductules present; 2 ϭ irregular buds of bile ductules affecting some portal tracts; 3 ϭ when bile ductules are more prominent and affect the majority of portal areas and/or strings of bile ductular epithelial cells were seen intermingled with hepatocytes. The degree of fibrosis ranged from 0 to 4 and was patterned after the Brunt system. 25 Briefly, this was as follows: 1 ϭ perisinusoidal/perivenular fibrosis alone; 2 ϭ 1 plus portal fibrosis; 3 ϭ bridging fibrosis; 4 ϭ cirrhosis. The assessment of the preceding scores was uniformly performed under 100ϫ magnification in 10 fields per sample and twice.
Immunohistochemistry
The collagen I antibody used on IHC was from Millipore (Billerica, MA), the FMOD and cytokeratin-19 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA), the ␣-smooth muscle actin (␣-SMA) antibody was from Sigma, and the desmin antibody was from Dako (Carpinteria, CA). The FMOD antibody was tested in livers from Fmod Ϫ/Ϫ mice and competed with rFMOD (2.5 g rFMOD and 2 g FMOD antibody in 1 mL were incubated for 30 min at room temperature) to ensure specificity (Supplementary Figure 1) . Reactions were developed using the Histostain Plus Detection System (Invitrogen, Carlsbad, CA). For the Sirius red computer-assisted morphometry assessment, the integrated optical density was calculated from 10 random fields per sample containing similar-size portal tract or hepatic vein at 100ϫ and using Image-Pro 7.0 Software (Media Cybernetics, Bethesda, MD). The results were averaged and expressed as fold change over controls.
Statistical Analysis
Data were analyzed by a 2-factor analysis of variance, and results are expressed as mean Ϯ SEM. All in vitro experiments were performed in triplicate at least 4 times. A represen- tative blot is shown in all figures. Eight mice per group were used in all the in vivo experiments, which were repeated twice.
Results
FMOD Increases in Patients With Stage 3 HCV-Induced Cirrhosis
To determine whether FMOD is expressed in human livers, resections from healthy patients and patients with biopsy-proven stage 3 HCV-induced cirrhosis were studied for FMOD protein and messenger RNA (mRNA) expression. Western blot analysis showed an increase in both FMOD and collagen I protein levels in patients with HCV-induced cirrhosis compared with healthy explants ( Figure 1A ). Likewise, there was an 8-fold increase in FMOD mRNA levels in patients with HCV-induced cirrhosis compared with healthy explants ( Figure 1B) . Hence, these results confirm that FMOD is expressed in human liver and that it is up-regulated in stage 3 HCV-induced cirrhosis.
Expression of FMOD Is Up-regulated in Cholestasis and in Drug-Induced Liver Injury in Mice
To dissect if FMOD also increased during liver injury in mice, we used well-established in vivo models of liver fibrosis such as common bile duct ligation (BDL), which causes cholestatic liver damage, or long-term CCl 4 injection and TAA treatment to provoke drug-induced liver injury. These 2 drugs undergo cytochrome P450 metabolism, leading to significant oxidant stress, inflammation, and pericentral necrosis.
FMOD protein was induced under chronic common BDL (Figure 2A ), CCl 4 injection ( Figure 2B ), and TAA treatment ( Figure 2C ). In all 3 models, FMOD expression was detected mostly in the sinusoids and in hepatocytes. FMOD protein expression in the BDL, CCl 4 , and TAA models was also validated by Western blot analysis ( Figure  2D ). Thus, there was an association between FMOD protein up-regulation and the extent of liver injury in mice. To identify the specific cell type that expressed FMOD, chronic CCl 4 -injured WT mouse livers were perfused and primary cells were isolated. Western blot analysis revealed that HSCs, hepatocytes, and SECs expressed and secreted FMOD protein ( Figure 2E and F) ; however, Kupffer cells did not express FMOD (not shown).
FMOD Activates and Induces Profibrogenic Effects in HSCs
Because FMOD protein was found induced in HSCs during liver injury, we hypothesized that endogenous FMOD could enhance activation of HSCs and their profibrogenic potential. To show this, rat HSCs were infected with Ad-LUC or Ad-FMOD. Adenoviral infection did not alter HSC viability or phenotype ( Figure 3A, left) . Along with enhanced intracellular FMOD expression, intracellular collagen I and to some extent ␣-SMA, a marker of HSC activation, were increased by Ad-FMOD compared with Ad-LUC infection ( Figure 3A, right) . Hence, an autocrine role for intracellular FMOD in modulating collagen I deposition and HSC activation could be established.
Because the IHC analysis also identified hepatocytes and SECs as sources of FMOD, and FMOD was secreted by all 3 cell types, next we questioned whether extracellular FMOD could play a role in regulating the profibrogenic phenotype of HSCs, which entails their proliferative, migratory, and invasive potential. To evaluate this, rat HSCs were challenged with rFMOD and cell proliferation, migration, and invasion were evaluated over time. rFMOD induced HSC proliferation by 35%, as shown by the rate of methyl[ 3 H]-thymidine incorporation into the DNA of HSCs ( Figure 3B ). Migration, measured by wound closure, was also enhanced by rFMOD treatment ( Figure 3C, arrows) , and it was not blocked by preincubation with mitomycin to inhibit mitosis (not shown). Lastly, HSC invasion or chemotaxis was increased by 6-fold in the presence of rFMOD when compared with nontreated cells (Figure 3D and E) . Overall, these findings show that FMOD also exerts a paracrine role in regulating the profibrogenic behavior and phenotype of HSCs.
ROS Increase FMOD Protein Expression
Because cholestasis and drug-induced liver injury generate a significant amount of ROS due to glutathione depletion and increased ROS generation, mostly via cytochrome P450 2E1 activation, 26 next we evaluated whether FMOD was ROS sensitive. First, HepG2 cells overexpressing cytochrome P450 2E1, as a source of ROS, were analyzed for FMOD expression. Western blot analysis showed significant up-regulation of both cytochrome P450 2E1 and intracellular and extracellular FMOD proteins ( Figure 4A ). In addition, primary rat HSCs incubated with H 2 O 2 displayed greater intracellular and extracellular FMOD expression than nontreated HSCs ( Figure 4B) .
To validate the induction of FMOD by oxidative stress in vivo, WT mice were injected with CCl 4 for 1 month in the presence or absence of S-adenosylmethionine, an antioxidant known to restore glutathione levels, or mineral oil. Coinjection with S-adenosylmethionine lowered by 50% FMOD protein levels (Supplementary Figure 2A) and the extent of liver fibrosis 27 when compared with mice injected with CCl 4 alone. Overall, these data indicate that FMOD is an ROS-sensitive proteoglycan. Because collagen I is highly inducible by oxidant stress, 28 FMOD could be a potential mediator regulating collagen I deposition.
Hepatocytes and SECs Increase FMOD and Collagen I Levels in HSCs in Coculture
Because in vivo models of cholestasis or druginduced liver injury identified hepatocytes and SECs as sources of FMOD in addition to HSCs, which were responsive to rFMOD, to analyze whether these cells also contributed to the fibrogenic response in a paracrine fashion, cocultures with HSCs were established. Primary rat HSCs were placed in coculture with either primary SECs or hepatocytes. Coculture with either cell type led to an increase in ROS levels (mostly hydroperoxides) in the cell culture medium compared with HSCs cultured alone. As anticipated, the increase in ROS was rather significant in the hepatocyte coculture compared with the SEC coculture ( Figure 5A) ; hence, based on our previous studies showing the effect of hepatocyte-derived ROS generation on the HSC profibrogenic behavior, 9,29 -32 we prioritized this coculture model.
Coculture of HSCs with SECs increased both intracellular FMOD and collagen I protein expression compared with the HSC monoculture; however, extracellular FMOD and collagen I were undetectable ( Figure 5B ). In contrast, coculture of HSCs with hepatocytes notably elevated both intracellular and extracellular collagen I and FMOD protein levels when compared with the HSC monoculture ( Figure 5C ). Thus, these results show that FMOD from neighboring cells could also signal to enhance the HSC profibrogenic response.
Lastly, because the coculture of HSCs with hepatocytes showed the highest increase in ROS levels, based on previous work, 9,29 -32 to determine whether ROS could be upstream of FMOD, the hepatocyte and HSC coculture was incubated in the presence of an antioxidant. Catalase, which decomposes H 2 O 2 and other hydroperoxides, prevented the increase in intracellular and extracellular collagen I as well as in FMOD and ␣-SMA levels in HSCs cocultured with hepatocytes, suggesting an ROS-dependent mechanism for the profibrogenic effects of FMOD on HSCs ( Figure 5D ).
FMOD Binds Collagen I but Does Not Prevent Collagen I Degradation by Matrix Metalloproteinase 13
Because the interaction between collagen I and FMOD could increase the stability of collagen I, hence favoring scarring, samples from cocultures of HSCs with hepatocytes were immunoprecipitated with anti-FMOD antibody and immunoblotted with anti-collagen I antibody. There was binding of FMOD and collagen I proteins (Supplementary Figure 3A) . Infection of HSCs with Ad-FMOD to overexpress FMOD and treatment with active matrix metalloproteinase 13, a key HSC protease known to degrade collagen I within the triple-helical structure, 33 did not alter collagen I degradation compared with HSCs infected with Ad-LUC and treated with active matrix metalloproteinase 13 (Supplementary Figure 3B) . Thus, the FMOD/collagen I binding in HSCs did not increase collagen I stability against matrix metalloproteinase 13 proteolytic degradation.
BDL Induces More Liver Injury and Fibrosis in WT Than in Fmod ؊/؊ Mice
Because the in vitro data suggested a profibrogenic role for FMOD, next we asked whether complete Fmod ablation could confer protection in the chronic BDL model. WT and Fmod Ϫ/Ϫ mice were either bile duct ligated or sham operated and killed 3 weeks later. Serum ␥-glutamyltransferase activity increased in BDL compared with sham-operated WT mice, whereas lower activity was observed in Fmod Ϫ/Ϫ mice ( Figure 6A ). H&E staining showed that coagulative necrosis, inflammation, and ductular reaction were present in BDL WT mice but were less apparent in Fmod Ϫ/Ϫ mice ( Figure 6B ). The scores for necrosis, portal inflammation, lobular inflammation, and ductular reaction validated these findings ( Figure 6C-F) . Lastly, IHC analysis depicted more desmin, collagen I deposition, Sirius red staining and morphometry, cytokeratin-19 (a marker for ductular reaction), and neutrophil staining in BDL WT than in Fmod Ϫ/Ϫ mice ( Figure 7A-E) ; however, similar transforming growth factor ␤ expression was detected by Western blot analysis and IHC (not shown) in CCl 4 -injected WT and Fmod Ϫ/Ϫ mice ( Supplementary Figure 2B) . Thus, Fmod ablation prevented BDL-induced fibrosis in mice.
WT Mice Show More CCl 4 -Induced Chronic Liver Injury and Fibrosis Than Fmod ؊/؊ Mice
To dissect whether Fmod ablation could be protective in a model of chronic drug-induced liver injury affecting mostly the central zone, 10-week-old male WT and Fmod Ϫ/Ϫ mice were treated with CCl 4 or mineral oil intraperitoneally for 1 month and were killed 48 hours after the last injection to prevent acute liver injury. H&E staining and pathology scoring according to the Brunt classification, collagen I IHC, Sirius red/fast green staining and morphometry, and ␣-SMA IHC revealed more inflammation, necrosis, fibrosis, and ␣-SMA expression in CCl 4 -injected WT mice than in Fmod Ϫ/Ϫ mice (Supplementary Figure 4) . These results confirm that Fmod deletion protects from liver fibrosis.
Discussion
The overall goal of this study was to determine the potential role of FMOD on the profibrogenic phenotype of HSCs and its contribution to the fibrogenic response to liver injury. Although previous work by Krull et al 19 did not identify Fmod mRNA in normal rat liver, our studies show that FMOD protein is expressed in human liver and is significantly elevated in patients with stage 3 HCVinduced cirrhosis compared with healthy individuals. Induction of FMOD has been previously described in bleomycin-induced pulmonary fibrosis in rats, 34 and FMOD gene transcription is induced by UV irradiation. 35 In addition, we show that FMOD expression is up-regulated in cholestasis in the BDL model and in drug-induced liver injury in the CCl 4 and TAA models in WT mice.
FMOD-positive staining was identified mostly in parenchymal and in sinusoidal areas. Specificity of the FMOD staining on IHC was further confirmed by using Fmod Ϫ/Ϫ mice by competing with rFMOD and by isolating primary cells from CCl 4 -treated WT mice. Hepatocytes, SECs, and HSCs, but not Kupffer cells, expressed FMOD protein. Thus, we speculated that the effects of FMOD on HSCs would be both of autocrine and paracrine nature because HSCs were exposed to secreted FMOD produced by themselves and by neighboring liver cells.
To evaluate the autocrine effects of FMOD on the HSC profibrogenic phenotype, intracellular FMOD was induced by infecting HSCs with Ad-FMOD. This resulted in an increase in intracellular and extracellular collagen I along with ␣-SMA, thus validating an autocrine role for FMOD in driving HSC activation and in promoting their profibrogenic potential.
To dissect whether extracellular FMOD could also condition the HSC behavior, cells were incubated in the presence of rFMOD, which caused an increase in HSC proliferation, migration, and invasive potential. These are important functions gained by HSCs during their activation process and greatly contribute to their profibrogenic ability. Thus, the experimental data suggest that FMOD activates and induces a profibrogenic response in HSCs in both an autocrine and a paracrine manner.
Oxidative stress represents a common link among different modes of persistent liver injury. Because FMOD is expressed in hepatocytes, SECs, and HSCs and FMOD was found to be ROS sensitive in vitro and in vivo, also described by others in fibroblasts, 36 we speculated that communication between these cell types could lead to an enhanced profibrogenic behavior in HSCs. Several studies, including our own, 3, 9, 37 have evaluated the role of conditioned medium from hepatocytes and SECs in stimulating HSCs. 31, 32 These studies have identified ROS as key mediators for the profibrogenic actions on HSCs.
To date, there is limited information on the specific ROS-sensitive mediators secreted by hepatocytes, SECs, and HSCs, as well as the molecular mechanisms by which these molecules modulate the fibrogenic response in HSCs. Thus, a coculture model was developed to study the role of hepatocytes and SEC-secreted FMOD on HSC activation and collagen I production. These models resemble aspects of the cross talk of hepatocytes and SECs with HSCs in vivo and have been previously used to gain mechanistic insight on the communication between these cell types. 2, 3 A novel role of FMOD as an ROS downstream effector on collagen I up-regulation and HSC activation was identified, which was blocked by catalase, an antioxidant.
Thus, FMOD could also convey paracrine-mediated signaling to regulate the profibrogenic behavior of HSCs; however, whether these effects require receptor binding and further intracellular signaling in HSCs still remains to be determined because the FMOD receptors, if any, have not been identified so far. In addition, FMOD did not exert its profibrogenic effects by modulating transforming growth factor ␤, a well-known profibrogenic factor, 14, 38 because Western blot analysis showed similar transforming growth factor ␤ expression in BDL Fmod Ϫ/Ϫ and in WT mice. Our studies also ruled out that the physical interaction between FMOD and collagen I could prevent the matrix metalloproteinase 13-mediated collagen I proteolysis in HSCs, thus contributing to ECM deposition.
All these results suggested that Fmod gene ablation could protect from the onset of liver fibrosis. The in vivo data showed that in the chronic BDL model, where significant periportal fibrosis occurs due to biliary hyperplasia, Fmod Ϫ/Ϫ mice developed less coagulative necrosis, inflammation, biliary epithelial cell proliferation, ductular reaction, and neutrophil infiltration than WT mice. Moreover, collagen I expression was lower in BDL Fmod Ϫ/Ϫ compared with WT mice, and comparable findings were obtained in mice treated with CCl 4 , which also depicted lower ␣-SMA induction.
In conclusion, our results identified FMOD as expressed in the liver and induced upon the onset of chronic liver injury. Furthermore, they suggest a role for the ROSdriven FMOD increase in regulating HSC activation and their profibrogenic potential both in an autocrine and a paracrine fashion; hence, FMOD could be considered as a new target to prevent the development and progression of liver fibrosis.
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proteins detected in cells after removing the cell culture medium and washing with phosphate-buffered saline twice; thus, some protein bound to the cells may still remain. Extracellular collagen I and FMOD refer to secreted unbound protein, precipitated with acetone (1:9, vol/vol) overnight and collected after centrifugation at 11,000g for 30 minutes. The quantification under the blots refers to the sum of bands from all collagen I and FMOD isoforms.
The enhanced chemiluminescence reaction was developed by using the Las4000 scanner (Fujifilm, Stamford, CT). The intensity of the Western blot bands was quantified using the National Institutes of Health Image J software. All Western blots were performed in triplicate from at least 4 different experiments. All samples from each experiment were run on the same gel and transferred onto the same nitrocellulose membrane. Extracellular proteins analyzed by Western blot were corrected by total protein content, and protein loading was subsequently verified by Ponceau red staining on each nitrocellulose membrane. The loading controls for intracellular proteins were calnexin or actin.
In Vivo Cotreatment With an Antioxidant
To determine the protective role of antioxidant treatment in vivo and its effects on FMOD expression, WT mice were injected intraperitoneally with CCl 4 or CCl 4 plus S-adenosylmethionine (SAM) for 1 month. SAM was administered at a dose of 10 mg/kg body wt daily and was always given 2 hours before the CCl 4 injection. Control groups received mineral oil or mineral oil plus SAM.
Collagen I Proteolysis
HSCs were infected with Ad-LUC or Ad-FMOD for 48 hours to allow FMOD overexpression as well as collagen I and FMOD in vitro binding. Samples of noninfected cells were used as controls for total collagen content. Matrix metalloproteinase 13 (MMP13) was preactivated by treatment with 2.5 mmol/L p-aminophenylmercuric acetate for 30 minutes. Cell lysate and culture medium were then incubated with preactivated MMP13 for 1, 2, 6, and 24 hours to allow for collagen I degradation in the presence or absence of overexpressed FMOD. The reactions were stopped by addition of 15 mol/L EDTA. Samples were neutralized, and a Western blot analysis for collagen I was performed. Collagen I proteolysis was detected by the disappearance of the highmolecular-weight bands corresponding to the ␣1 and ␣2 collagen I and the appearance of lower-molecular-weight bands in the blot.
